Halozyme Therapeutics (HALO) Misses Q4 EPS by 9c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Nasdaq hits near three-month low as Amazon, Intel deepen AI capex concerns
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil set for fourth monthly gain as Hormuz tanker attack highlights supply risks
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $131.05 -0.1%
EPS Growth %: +32.6%
Financial Fact:
Revenues under collaborative agreements: 5.49M
Today's EPS Names:
BNCC, ZVOI, SYRS, More
EPS Growth %: +32.6%
Financial Fact:
Revenues under collaborative agreements: 5.49M
Today's EPS Names:
BNCC, ZVOI, SYRS, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of ($0.24), $0.09 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $53.7 million versus the consensus estimate of $56.93 million.
GUIDANCE:
Halozyme Therapeutics sees FY2020 EPS of $0.60-$0.75, versus the consensus of $0.58. Halozyme Therapeutics sees FY2020 revenue of $230-245 million, versus the consensus of $220.7 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stifel on FedEx Freight (FDXF): 'Enters Its Post-Breakup Era - Time to Hit the Gym and Focus on Itself'
- Arbor Realty Trust (ABR) Misses Q3 EPS by 8c
- Federal Realty Inv. Trust (FRT) Tops Q3 EPS by 3c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
